EYPT 250117 10.00P (EYPT250117P10000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

EYPT250117P10000

Watchlist

2.02
+0.02+1.00%

15min DelayTrading Jan 3 09:47 ET

2.02High2.02Low

Intraday

5D
Daily

News

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswireDec 16, 2024 07:00 ET
H.C. Wainwright Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $22
Moomoo NewsDec 5, 2024 12:31 ET · Ratings
EyePoint Pharmaceuticals Price Target Maintained With a $22.00/Share by HC Wainwright & Co.
Dow JonesDec 5, 2024 06:30 ET · Ratings
EyePoint Pharmaceuticals Analyst Ratings
BenzingaDec 5, 2024 06:18 ET · Ratings
Express News | EyePoint Pharmaceuticals Inc - Topline Data for Phase 3 Pivotal Program Expected in 2026
ReutersDec 4, 2024 07:00 ET
Express News | EyePoint Announces First Patient Dosed in Second Global Phase 3 Lucia Clinical Trial of Duravyu™ for the Treatment of Wet Age-Related Macular Degeneration
ReutersDec 4, 2024 07:00 ET

Comments

Jaguar8

Nov 7, 2024 21:34

13G

$EyePoint Pharmaceuticals (EYPT.US)$
EyePoint Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-TCG Crossover GP II, LLC(5.2%),TCG Crossover Fund II, L.P.(5.2%), etc.

Jaguar8

Nov 7, 2024 15:14

NEWS ER

$EyePoint Pharmaceuticals (EYPT.US)$
Positive
Positive interim DME trial data showing significant BCVA improvement of +8.9 letters
Successful completion of $161M equity financing
Extended cash runway into 2027
Initiation of Phase 3 LUGANO trial in wet AMD
Opening of new 40,000 sq ft cGMP manufacturing facility
Negative
Revenue declined 31% YoY to $10.5M from $15.2M
Net loss increased to $29.4M from $12.6M YoY
Operating expenses increased to $43.3M from $29.6M YoY
Cash position decreased to...

Trytosaveabit

Oct 28, 2024 16:25

Oophff news

$EyePoint Pharmaceuticals (EYPT.US)$ Reuters· 8 mins ago
EyePoint Pharmaceuticals Inc - Commences $100 Million Public Offering

Stock_Drift

Oct 28, 2024 10:08

Unusual Volume Ticks. 11:07am 10/28

$Fractyl Health (GUTS.US)$ $Pixie Dust Technologies(Delisted) (PXDT.US)$ $Oklo Inc (OKLO.US)$ $Revance Therapeutics (RVNC.US)$ $PROCEPT BioRobotics (PRCT.US)$ $Atlas Lithium (ATLX.US)$ $EyePoint Pharmaceuticals (EYPT.US)$ $Porch Group (PRCH.US)$ $Top Wealth Group Holding (TWG.US)$ $Global Mofy AI (GMM.US)$ $Monte Rosa Therapeutics (GLUE.US)$ $Evoke Pharma (EVOK.US)$ $Greenlane (GNLN.US)$ $Autonomix Medical (AMIX.US)$ $Healthcare Triangle (HCTI.US)$
📊⚡️📊

Trytosaveabit

Oct 28, 2024 06:07

Update

$EyePoint Pharmaceuticals (EYPT.US)$ EyePoint's DURAVYU Shows Results for Diabetic Macular Edema, Improving Vision and Anatomy in Early Trial Data! Favorable Safety Profile Continues With No Duravyu-Related Ocular or Systemic Saes to Date
Benzinga· 2 mins ago